Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Parallel-group, Double-blind Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

Trial Profile

A Randomized, Parallel-group, Double-blind Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Vilaprisan (Primary)
  • Indications Uterine leiomyoma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASTEROID 7
  • Sponsors Bayer
  • Most Recent Events

    • 04 Feb 2019 Planned End Date changed from 15 Oct 2020 to 14 Jul 2021.
    • 04 Feb 2019 Planned primary completion date changed from 15 Jul 2020 to 14 Jul 2021.
    • 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top